Clinical Trials Browser

PF06821497 × 30 days × Clear all

NCT03460977 2026-03-13

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Phase 1 Recruiting

LymphoidThoracic

Lymphoma, Follicular, Recurrence, Small Cell Lung Carcinoma

NCT06551324 2026-03-04

MEVPRO-1

Phase 3 Recruiting

Prostatic Neoplasms, Recurrence

NCT06629779 2026-03-04

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Phase 3 Recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT07028853 2026-03-04

MEVPRO-3

Phase 3 Recruiting

Prostatic Neoplasms